Coronary heart disease
Conditions
Interventions
2:Aspirin enteric-coated tablets combined with Ticagrelor
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients treated with ticagrelor / aspirin and ticagrelor; 2. Male or non-pregnant or non-lactating female patients >= 18 years of age. 3. Coronary heart disease patients with PCI indications and successful implantation of drug-coated stents and PRECISE DAPT score >= 25; 4. The subjects volunteered to join the study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients using anticoagulants 2. Active massive bleeding or life-threatening bleeding during screening 3. Known history of chronic HF prior to screening 4. Cardiogenic shock within the last 24 hours prior to randomization 5. Coronary artery bypass graft (CABG) performed or planned for index MI 6. Contraindications for anticoagulant or antiplatelet therapy, or an unacceptable risk of bleeding; 7. History of hypersensitivity to the study drugs or drugs of similar chemical classes or known intolerance or contraindications to study drugs or drugs of similar chemical classes including rivaroxaban ,ticagrelor. 8. Known hepatic impairment (as evidenced by total bilirubin > 3.0 mg/dL or increased ammonia levels, if performed), or history of cirrhosis with evidence of portal hypertension such as esophageal varices 9. There is a need for patients to continue to receive non-steroidal anti-inflammatory drugs (NSAIDs). 10. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin) within the past 3 years with a life expectancy of less than 1 year. 11. Patients with severe peripheral vascular diseases (carotid plaques, etc.), chronic obstructive pulmonary disease, acute and chronic infectious diseases, hematological diseases, immune system diseases, malignant tumors, etc. 12. Those who were participating in another clinical trial had not yet reached the end of the study or were planning to participate in another clinical trial within six months of taking the drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical hemorrhagic events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet aggregation function; | — |
Countries
China
Contacts
Public ContactZhang Bo
The First Affiliated Hospital of Dalian Medical University
Outcome results
None listed